FBS Levels Research Articles

Studies on genesis of Prameha from Amajirna w.s.r. to biochemical parameters

Background: In classical text it had been highlighted that Amajirna is root cause to produce Prameha. Musta is drug which combat Amajirna and it also effective to cure Prameha. So, this gives reasons for need of the present study and also reason for selection of topic. Aim: To evaluate the pathogenesis of Prameha from Amajirna and the efficacy of Musta (Cyperous rotundus) in both Amajirna and Prameha. Material and Methods: This study is an open label, randomized, interventional, comparative, prospective, controlled clinical trial. In the present study the patient of Prameha were enrolled following the subjective criteria of Prameha. A total of 60 patients of Prameha were selected from the OPD and IPD of Shyamadas Vaidya Shastra Pith Hospital, Kolkata, West Bengal, and randomly allocated with a computerized randomization method into two groups. Those selected patients were subjected for a confirmatory biochemical analysis of FBS and PPBS. The prediabetic person was interrogated for Amajirna as a past history or present illness, by the subjective criteria of Amajirna. In group A (n= 30), Musta Churna was given for 90 days and in group B (n= 30), Pippali Churna was given for 90 days. Before treatment and after treatment data FBS, PPBS, HBA1C, SGOT, SGPT, serum amylase, serum lipase and alkaline phosphatase enzyme levels were recorded for statistical analysis. This record of assessment was taken at 0, 30, 60 and 90 days. Wilcoxon signed rank test; unpaired t-test were applied. Result: Both groups showed statistically significant (p<0.05) improvement in chief complaints of Prameha, Amajirna, FBS, PPBS, HBA1C, SGOT, SGPT, serum amylase, serum lipase and alkaline phosphatase. Conclusion: On percentage wise comparison, better relief was found in Group-A i.e., Musta Churna was found to be more effective in all the subjective and objective parameters than Group-B (Pippali Churna).

The relationship between serum CTRP-5, C3a/desArg, and complement-C3 levels and hypothyroidism in women with polycystic ovary syndrome

IntroductionMany patients with polycystic ovary syndrome (PCOS) also experience thyroid disorders. There is a notable similarity in energy metabolism among PCOS, C1q/tumor necrosis factor (TNF)-related proteins (CTRP-5)deficiency, C3a/desArg (also known as acylation-stimulating protein (ASP)) deficiency, and hypothyroidism. This study aimed to investigate the relationship between serum levels of these factors and hypothyroidism in patients with PCOS. Improved clarity and vocabulary, corrected minor grammatical issues, and enhanced readability.MethodsThis case-control study involved three groups: healthy women (control group), women with PCOS and hypothyroidism, and women with PCOS without hypothyroidism. Serum levels of FBS, total cholesterol, triglycerides, and HDL-C were measured using enzymatic and colorimetric methods. TSH, T4, T3, and anti-thyroid peroxidase (Anti-TPO) levels were determined by ELISA to screen for hypothyroidism in women with PCOS. Additionally, serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), CTRP-5, ASP, and complement C3 were assessed using the ELISA method.ResultsThe results indicated that reduced blood levels of CTRP-5, along with elevated levels of ASP (C3a/desArg) and complement C3 in patients with PCOS, may be linked to dysregulation of the thyroid gland. Furthermore, the study observed that changes in these parameters, in conjunction with thyroid dysfunction, are associated with pathological alterations in lipid profiles and blood glucose levels.ConclusionWhile changes in CTRP-5, ASP, and complement C3 can influence energy expenditure and storage in PCOS and thyroid function, the complex nature of PCOS requires further research to investigate the prevalence of hypothyroidism in individuals with PCOS.Clinical trial numberNot applicable

Effectiveness and Safety of Metformin, Teneligliptin, and Glimepiride Combination Therapy in Type 2 Diabetes: A Quasi Experimental Clinical Trial.

Type 2 Diabetes Mellitus (T2DM) accounts for more than 95% of all diabetes cases and is a leading cause of disability and death. This study aimed to evaluate the effectiveness and safety of a combination therapy involving metformin, teneligliptin, and glimepiride in patients diagnosed with T2DM. The present quasi-experimental clinical trial involved 300 adult T2DM patients. They were divided into three groups: Group 1 (Metformin; n=100), Group 2 (Metformin + Teneligliptin; n=100), and Group 3 (Metformin + Teneligliptin +; n=100). Along with demographic data, we collected information on HbA1c, FBS, and PPBS levels, as well as fasting insulin, CPeptide, HOMA-IR, QUICKI-IR, and lipid, renal, and hepatic profiles at baseline and after 3, 6, and 12 months. Data analysis was performed using SPSS 21.0 software. A total of 300 patients participated in the study. At the end of 12 months, triple-drug therapy achieved significant glycemic control (HbA1c: 6.56±0.50%; P<0.0001) and reduced FBS (7.6±1.41 mg/dl; P<0.0001), PPBS (9.39±2.14 mg/dl; P<0.0001), and fasting insulin (11.26±2.5 IU; P<0.0001), C-peptide (2.01±2.29 ng/ml; P<0.0001), and insulin resistance by HOMA-IR (3.74±0.7; P<0.0001). Favorable lipid profiles (P<0.0001) were noted versus other groups. Despite renal and hepatic profile variations, values remained within the normal range. The combination of teneligliptin with metformin and glimepiride in T2DM patients demonstrated significant improvements in glycaemic control, reduced insulin resistance, and positive effects on lipid, renal, and hepatic profiles. Importantly, the therapy did not result in serious adverse drug reactions, such as hypoglycemia. We need more RCTs to substantiate these findings.

Undiagnosed hypertension and diabetes mellitus in the Tabari cohort: a population-based study

BackgroundUndiagnosed hypertension (HTN) and diabetes mellitus (DM) are major public health challenges worldwide. We aimed to investigate the prevalence of undiagnosed HTN and DM, and their correlates, in a large-scale population-based cohort study.MethodsIn this cross-sectional study, data collected during the enrollment phase of the Tabari Cohort study (TCS) were utilized. Data were collected in the TCS using a standard questionnaire, blood collection, and measurement of anthropometric indices and blood pressure. Data were analyzed using the chi-squared test and univariate and multivariate logistic regression analyses. Undiagnosed HTN included those who were not aware of HTN at the time of enrollment but had systolic and diastolic blood pressures ≥ 140 mm or ≥ 90 mmHg, respectively. Undiagnosed DM included participants who were unaware of their DM at the time of enrollment and had FBS levels ≥ 126 mg/dL.ResultsThe total prevalence of undiagnosed HTN and DM were 5% (508) and 4.7% (485), respectively. The findings of multivariable logistic regression analysis showed that young age (OR: 0.40, P < 0.001), residents of urban regions (OR: 0.70, P = 0.03), lower Body Mass Index kg/m2 (BMI) (OR: 0.51, P = 0.002), waist-to-hip ratio (WHR)(OR: 0.70, P = 0.023), total cholesterol (TC) ≥ 200 mg/dL (OR: 0.1.83, P < 0.001), lack of history of DM (OR: 0.38,P < 0.001), cardiovascular diseases (CVD)(OR: 0.12, P < 0.001), and lack of a positive family history of HTN in first-(OR: 0.39, P < 0.001) and second-degree(OR: 0.56, P = 0.009) relatives were the main predictors of undiagnosed HTN. Accordingly, male sex(OR: 0.52, P = 0.004), young age(OR: 0.28, P < 0.001), residence in urban regions(OR: 0.30, P < 0.001), BMI ≥ 30 (OR: 1.51, P = 0.044), low-density lipoprotein (LDL) ≥ 130 mg/dL (OR:1.93, P < 0.001), TC ≥ 200 mg/dL (95% CI, 1.47–2.51, P < 0.001), positive history of chronic kidney disease (OR:1.39, P = 0.010 ), and lack of family history of first-(OR: 0.38, P < 0.001) and second-degree (OR: 0.62, P < 0.015) DM were the main predictors of undiagnosed DM.ConclusionOverall, younger participants, those residing in urban areas, those with TC ≥ 200 mg/dL, and those without a positive family history of HTN or DM were at a greater risk of undiagnosed HTN/DM.

Evaluation of Antioxidant, Antibacterial and Antidiabetic Activity of &lt;i&gt;Juglans regia&lt;/i&gt; Root Extract: &lt;i&gt;In Vitro&lt;/i&gt; and &lt;i&gt;In Vivo&lt;/i&gt; Studies

Background: Diabetes mellitus is a long-term metabolic illness that occurs due to a malfunction in the production or action of insulin. Prolonged hyperglycemia may lead to dysfunction and failure of several organs, such as the diabetic nephropathy, retinopathy and neuropathy. The incidence of diabetes and the number of patients has consistently risen over the last several decades. Juglans regia, a member of the Juglandaceae family, has been used by practitioners of folklore to treat number of illnesses. Aim: To Evaluate the antioxidant and anti-bacterial effects of a root extract from Juglans regia in in vitro studies and anti-diabetic effect Streptozotocin (STZ) induced Wistar albino rats. Methods: Qualitative phytochemical analysis, antioxidant assay were done using DPPH, antibacterial assay have been performed by using agar well diffusion method and anti-diabetic effect tested by inducing rats with STZ followed by administering methanolic root extract of Juglans regia alone and with adjuvants metformin and glipalamide. Result: The root extract of Juglans regia can decrease free radicals, possess antibacterial property in agar well diffusion method and in in-vivo studies group 2 (diabetic control) showed elevated FBS and HbA1C from day 3 to day 28 while group 3, 4, 5, 6, 7 and 8 showed significant reduction in FBS and HbA1C levels at the end of study. Safety profiles such as CBC, RFT and LFT did not show any significant difference between the groups from baseline to end of the study. Thus, methanolic root extract of Juglans regia was safe and efficacious against STZ induced rats. Conclusion: Juglans regia can reduce hyperglycemia in STZ induced diabetic rats alone and can be used as an adjuvant to Metformin and Glibenclamide. Also, it possesses anti-oxidant and anti-bacterial activity in in vitro studies.

Prevalence of Hypovitaminosis D and its Association with Serum Lipids in Patients with Type 2 Diabetes Mellitus

Background Hypovitaminosis D has become worldwide public health concern affecting all age groups and both genders. Its prevalence is very high in South Asia. Many studies reported that vitamin D deficiency is concerned with diabetes mellitus and impaired glucose tolerance. The aim of this research was to find the prevalence of hypovitaminosis D and its association with serum lipids among type 2 diabetic patients.MethodsA cross-sectional study, conducted among a total 162 patients with type 2 diabetes mellitus in Manipal Teaching Hospital, Pokhara. The serum level of FBS, PPBS, urea, creatinine, calcium and phosphorus, HbA1c, TG, TC, HDL-C, and vitamin D levels were measured. In the descriptive categorical data were reported in frequency with percentage and numerical data were presented as mean±SD while in inferential statistics to compare the value student t-test were used. p-value&lt;0.05 was considered as statistically significant.ResultsThe mean±SD serum level of vitamin D was 24.48 ± 13.21 ng/mL in patients with type 2 diabetes. The prevalence of hypovitaminosis D was 69.14% (With 95% CI as 62.02 to 76.25%) and sufficient of vitamin D in 30.86% (With 95% CI as 23.74% to 37.97%) among patients with type 2 diabetes. The serum lipids showed statistically insignificant association between hypovitaminosis D with sufficient of vitamin D.Conclusions This research showed that only in one third of the patients had Vitamin D sufficiency. The serum lipids were slightly increased in patients who had hypovitaminosis D.

Effect of a multidisciplinary program with seven color balls on non-communicable diseases prevention in a Muslim community: A real-world study

Prevalence of diabetes and hypertension are increasing. Health promotion is needed for the diseases prevention. The objective of this study was to determine the impact of a multidisciplinary program and a seven-color balls on fasting blood glucose and blood pressure in a Muslim community. A one-group pre-post test of participatory action research was employed. The screening test was administered and assigned a color to each of seven health statuses. All participants made a commitment to improve their weekly performance. They were instructed and practiced for three weeks on six health information topics. Then, each village health volunteer reminded the participants of health information, and a religious leader declared (Kutbah) during Friday prayer that tobacco and alcohol are contrary to Islam. Utilizing frequency and percentage, the study outcome at the end of the program was compared to that at baseline. The results revealed that the mean age of the participants was 33.92 years, with a range of 15 to 82 years. Six months after program finish, 87.5% of those at risk and 93.3% of high risk for hypertension returned to normal blood pressure levels. For FBS level, risk for diabetes participants improved to a normal level by 57.6%, participants who were possibly for diabetes improved to better level by 50%, and third level illness decreased to a lower level by 50%. The program could improve participants’ health status and encourage their self-esteem for health prevention. Prevention of hypertension, and diabetes is essential for promoting individual and community health.

Association between IL-6 -174 G/C (rs1800795) and IL-1A -889 C/T (rs1800587) cytokine variants with polycystic ovary syndrome in Iranian women: A case-control study

Background and AimInfertility in women has various causes, one of which is ovulation disorders. Polycystic ovary syndrome (PCOS) affecting ovulation is a complex idiopathic disease in which genetic polymorphisms may be involved. This study aimed to investigate the relationship between IL-6 -174 G/C and IL-1A -889 G/A cytokine polymorphisms with polycystic ovary syndrome in a population of Iranian women. Materials and MethodsIn this case-control pilot study, 120 PCOS patients (60 infertile, LPI, and 60 women with recurrent pregnancy abortion, LPA) and 60 controls, CTRLs) participated. After genomic DNA extraction from peripheral blood, we investigated for the polymorphisms rs1800795 of the IL-6 -174 and rs1800587 of the IL-1A-889 using specific primers and PCR-RFLP followed by NlaIII enzyme digestion and PCR-ARMS techniques. ResultsThere was a significant difference in the studied groups in terms of clinical characteristics (p-value < 0.05) except for the levels of HDL and LDL. Regarding demographic and clinical characteristics of patients, a significant correlation was observed between C/G and G/G genotypes of rs1800795 and FBS level (p value = 0.002). Also, rs1800587 showed a substantial relationship between CC and CT genotypes with the level of LH in LPI and the level of FBS in the LPAs (p value = 0.04). There was no significant difference between the frequencies of rs1800795 and frequencies of rs1800587 genotypes in the three studied groups (p value > 0.05).The studied variants were in Hardy-Weinberg equilibrium. ConclusionThe present work showed that rs1800795 and rs1800587 were not directly associated with PCOS in Iranian patients while the SNPs showed an indirect relationship with some factors affecting the disease.However, using genome-wide association analysis is a proper suggestion to obtain more reliable information about the disease’s genetic view. To our knowledge, this is the first report that implicates the role of the examined SNPs in an Iranian PCOS population.

Comparison of Glucose and Immunoglobulin a Levels in Serum and Saliva of Patients with Type 1 and Type 2 Diabetes

Introduction: The monitoring and management of blood glucose levels are of significant importance in individuals diagnosed with diabetes mellitus. Accordingly, the objective of this study was to examine the potential of a non-invasive approach for the diagnosis and management of diabetes, through the measurement of glucose concentration and salivary IgA, and a comparison with fasting glucose and serum IgA levels in individuals with type 1 and 2 diabetes, in relation to a control group of healthy individuals. Methods: This case-control study was conducted on 76 individuals with diabetes (31 with type 1 diabetes and 45 with type 2 diabetes) and 24 healthy individuals. After obtaining the code of ethics and informed consent, serum and salivary IgA levels as well as fasting glucose, were measured for each participant. The data were analyzed using SPSS version 16 statistical software and the Spearman, Kruskal-Wallis, and Mann-Whitney tests. Results: The results showed a significant difference among the three groups (type 1 diabetes, type 2 diabetes, and healthy group) based on Fasting Blood Glucose, Hemoglobin A1c, Immunoglobulin A, salivary sugar, and salivary IgA (p&lt;0.001). Additionally, in the case group, parameters such as FBS, HbA1c, and salivary IgA showed a significant correlation with salivary sugar. Conversely, in the control group, only the salivary sugar level demonstrated a significant relationship with serum glucose level. The study's findings indicated that serum and salivary IgA levels were lower and higher, respectively, in the control subjects compared to the diabetic group (p&lt;0.001). Conclusion: In healthy individuals, salivary sugar can serve as an indicator to determine fasting blood sugar levels. In diabetic patients, salivary sugar can predict of FBS, HbA1c, and salivary IgA levels.

Role of urinary nephrin to predict early onset of nephropathy in patients with type 2 diabetes mellitus

Nephropathy is most common complication in type 2 diabeticsubjects. Urinary nephrin is a podocyte specific protein, can be serve as a predict early nephropathy and its progression of diabetic nephropathy. A total 90 participants included were sub grouped as 60 cases and 30 healthy controls, a biochemical, clinical and experimental parameters were analyzed for all the study subjects. The data was interpreted by using statistics software SPSS and &amp;#60;0.05 was statistically significant. There were significantly increased levels of FBS, PPBS and glycated haemoglobin in type 2 diabetic cases when compared to controls. The urea, creatinine, uric acid and microalbumin were significantly elevated in type 2 diabetic with microalbuminuria when compared to type 2 diabetic with normoalbuminuria and controls. Additionally the urinary nephrin was significantly elevated in both groups of type 2 diabetics when compared to controls. This study suggests determination of urinary nephrin can be used as an early predictable and prognostic marker for nephropathy in patients with type 2 diabetics.

Relationship between types and levels of free fatty acids, peripheral insulin resistance, and oxidative stress in T2DM: A case-control study.

Free Fatty Acids (FFAs) are vital for energy homeostasis and the pathogenesis of a variety of diseases, including diabetes. For the first time, we presumed and investigated the types and levels of FFAs and their links to Insulin Resistance (IR) and Oxidative Stress (OS) in T2DM. A case-control study was conducted on 60 individuals with diabetes, 60 prediabetics with IFG, and 60 control groups. A Gas Chromatography Flame Ionization Detector (GC-FID) was used to estimate FFAs, which were then classified based on length and saturation. Indeed, antioxidant parameters such as TAC, MDA levels, PON-1, SOD-3, and CAT activity were assessed. Higher levels of LCFFA, SFFA, USFFA, and total FFA were found in people with diabetes and prediabetes. These levels were also linked to higher levels of HOMA-IR, BMI, FBS, HbA1C, and MDA, but lower levels of antioxidants. Furthermore, adjusting the above FFAs with age, sex, and antihypertensive medication increased T2DM development. SCFFA and ω3/6 fatty acids had a negative relationship with HOMA-IR, FBS, and insulin and a positive relationship with TAC. Adjusted SCFFA reduces T2DM risk. According to our models, total FFA is utilized to diagnose diabetes (AUC = 83.98, cut-off > 919 μM) and SCFFA for prediabetes (AUC = 82.32, cut-off < 39.56 μM). Total FFA (≥ 776 μM), LCFFA (≥ 613 μM), SFFA (≥ 471 μM), and USFFA (≥ 398 μM) all increase the risk of T2DM by increasing OS, BMI, and HOMA-IR. On the other hand, SCFFAs (≥ 38.7 μM) reduce the risk of T2DM by reducing BMI, HOMA-IR, and OS. SCFFAs and total FFAs can be used for the diagnosis of prediabetes and diabetes, respectively.

Investigation of Glycated hemoglobin (HbA1C) and Serum Ferritin Levels in Diabetic Patients with Poor Glycemic Control in Benin City, Edo State, Nigeria

Aim/ Objective: Uncontrolled diabetes mellitus is a metabolic disorder characterized by persistent hyperglycaemia and associated complications. Assessing ferritin and glycated haemoglobin (HbA1c) levels in diabetic patients can provide valuable insights into the management and progression of the disease. This study was aimed at assessing the ferritin and HbA1c levels in patients with uncontrolled diabetes mellitus and evaluate the clinical implications of these assessments. Methodology: This was a case-control study, comprising of 60 consenting participants including 30 uncontrolled diabetes patients, 15 controlled diabetic patients, and 15 non-diabetic with no history of the disease serving as controls. Ferritin levels were measured using enzyme-linked immunosorbent assay (ELISA), and HbA1c levels were also determined using modified enzymatic reaction. Demographic and clinical data, including age, gender, diabetes duration, and medication history, were collected via questionnaires. Results: Analysis of variance (post-hoc) indicated significantly (p &lt; 0.001) higher FBS, HbA1c and ferritin in patients with uncontrolled diabetes compared with the non-diabetic individuals. In contrast, there was no significant difference (p = 0.973) in mean ferritin between patients with controlled diabetes and those with uncontrolled diabetes. In the entire study population, there was a significant relationship between ferritin and FBS (p = 0.001) and HbA1c (p &lt; 0.001) level. Conclusion: In this study, the levels of FBS, HbA1c and ferritin were higher among the uncontrolled diabetes patients. This suggests the need to include ferritin in the panel of assay when screening for diabetes mellitus and when monitoring the progression of the disease.

Anti-diabetic activity of aqueous extract of Trichilia prieureana A. Juss leaves in fructose-fed streptozotocin-induced diabetic male Wistar rats

Background and aimEthanolic extract of Trichilia prieureana leaves have been reported to exhibit anti-hyperglycemic activities without detailed information on the anti-diabetic activities. This study investigated the anti-diabetic activity of aqueous extract of T. prieureana leaves (AETPL) in type 2 diabetic (T2DM) male rats. Experimental procedureT2DM rats (induced with 10 % fructose solution ad libitum for 2 weeks and streptozotocin [STZ]; 40 mg/kg body weight {BW}) in groups B, C, D, E, and F were also administered distilled water (DW), metformin (100 mg/kg BW), 11.2, 22.3, and 44.6 mg/kg BW of AETPL, respectively, whilst non-diabetic rats in Group A received DW only (Sham Control, SC) for 14 days. The T2DM-related parameters were then evaluated. ResultsThe fructose-fed streptozotocin-(FSTZ) treatment related significant (p < 0.05) increases in FBS, HbA1c, fructosamine, HOMA-IR, G6P, GP, TC, TG, LDL-C, urea, bilirubin, hepatic and pancreatic MDA levels; decreases in BW, serum insulin, creatinine, albumin, HOMA-β, glycogen, G6PD, HK, HDL-C, hepatic and pancreatic SOD, GPX, RG, catalase, Hb, PCV, MCH, MCHC, MCV, RBC, WBC, differentials and the destruction of the pancreatic β-cells, hepatocyte degeneration, and central hepatic vein congestion were reversed by AETPL, to values that compared well with SC in most cases. In the IpGGT model, the intraperitoneally administered AETPL reduced the blood glucose and elevated the plasma insulin levels. The AETPL at 44.6 mg/kg BW exhibited the most pronounced effects. ConclusionAETPL (44.6 mg/kg BW) restored T2DM-glycemic control and associated biochemical changes via up-regulation of insulin, carbohydrate metabolizing enzymes and restoration of pancreatic and hepatic histoarchitecture.

The effect of USM-IAM-based counselling vs standard counselling on insulin adherence, FBS and HbA1c among patients with uncontrolled type 2 diabetes mellitus (T2DM): a randomised controlled trial

BackgroundMany patients with T2DM on insulin are not optimally controlled despite receiving standard diabetes education counselling. Poor insulin adherence may be a contributing factor. We developed and evaluated a new module [Universiti Sains Malaysia-Insulin Adherence Module (USM-IAM)] on insulin-treated patients with poorly controlled diabetes.MethodsEligibility criteria are those diagnosed with T2DM, aged between 18 and 65 years, with HbA1c between 8 and 15% and on insulin therapy for 1 year. Patients were randomly allocated to receive either the USM-IAM-based counselling or the standard counselling (SC) at baseline and the second visit. Patients were instructed to adjust insulin doses based on blood glucose levels. Outcomes were changes in adherence score, FBS and HbA1c levels from baseline to 3 months and baseline to sixth month.ResultsNinety patients were randomised to each group. The baseline sociodemographic and clinical characteristics were homogenous among groups. Ninety patients were analysed for each group. Adherence score changes between baseline to 3 months were − 8.30 (− 11.47, − 5.14) in USM-IAM-based counselling group (USM-IAM) and − 7.64 (− 10.89, − 4.40) in standard counselling group (SCG), between baseline to sixth month were − 10.21 (− 13.40, − 7.03) in USM-IAM and − 10.79 (− 14.64, − 6.97) in SCG. FBS changes between baseline to 3 months were 1.374 (0.25, 2.50) in USM-IAM and 0.438 (− 0.66, 1.54) in SCG, and between baseline to sixth month were 1.713 (0.473, 2.95) in USM-IAM and 0.998 (− 0.02, 2.01) in SCG. HbA1c changes between baseline to 3 months were 1.374 (0.25, 2.50) in USM-IAM and 0.547 (0.12, 0.98) in SCG, and between baseline to sixth month were 1.03 (0.65, 1.41) in USM-IAM and 0.617 (0.20, 1.03) in SCG. Between-subjects effects for all outcomes were not statistically significant.ConclusionBoth groups had significant improvements in adherence score and HbA1c with time, with higher improvement in patients receiving the USM-IAM. FBS reductions were significant in the intervention group but not in the control group.Trial registrationThis study protocol is registered with Clicaltrials.gov with ID NCT05125185 dated 17th November 2021.

Relationship between Serum Zinc Level and Retinopathy in Type 2 Diabetic Patients

Abstract Background Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia caused by insulin resistance (IR) or impaired insulin production. Diabetic retinopathy (DR) is a common microvascular disorder which occurs in type 2 diabetes mellitus (T2DM) patients due to chronic hyperglycemia. Previous studies reported that serum zinc (Zn) was associated with certain diabetic microvascular complications. Objective To evaluate relation between serum zinc level and diabetic retinopathy in patients with type 2 diabetes mellitus. Subjects and Methods The current study included 60 subjects with their ages ranging from 18- 60, selected from diabetes and ophthalmology outpatient clinics of Ain Shams University Hospitals for 7 months in a period from July 2022 to January 2023 with matched age and sex . fasting and post prandial blood glucose, hemoglobin A1c (HbA1c), systolic blood pressure (SBP), diastolic blood pressure (DBP),serum creatnine, LDL, HDL, TG,TC and serum zinc levels were measured among groups. Results The study shows statistically significant difference between DM type II subgroups regarding duration of disease (yrs) being higher in DM II with retinopathy 12.5 (10.5 – 16.5) than DM II without retinopathy 9 (6 – 12) with p &amp;lt; 0.001. serum Zn levels were significantly lower in the DR group than the controls and diabetic without retinopathy.in whole DM type II group, there was statistically significant negative correlation found between zinc level and duration of diabetes, HbA1c, LDL, TC, FBS, 2PP and serum creatinine level, while in DM II without retinopathy there was statistically significant negative correlation found between zinc level and duration of diabetes, LDL, TC and FBS and also in DM type II retinopathy there was statistically significant negative correlation found between zinc level and duration of diabetes, HbA1c, FBS, 2PP and serum cretainine level .There is no statistically significant difference found between control group and DM type II group regarding weight, height and BMI of the studied patients with p-value = 0.108, 0.198 and 0.343; respectively. There is no statistically significant difference found between control group and DM type II group regarding systolic and diastolic blood pressure of the studied patients with p- value = 0.554 and 0.405; respectively. Conclusion Our study suggested that lower serum zinc level in T2D patients was related to higher prevalence of diabetic microvascular complications. Patients with lower serum zinc level were more likely to have a longer duration of diabetes, poorer glucose control, and worse β-cell function. Older age, higher HbA1c level, and the prevalence of DN were risk factors related to the lower serum zinc level.

Understanding the Association Between Type 2 Diabetes Mellitus and Cognitive Impairment: A Single-centre Experience.

The global prevalence of diabetes mellitus has been increasing, leading to a rise in morbidity associated with the disease. While diabetic nephropathy, retinopathy and neuropathy are routinely screened in diabetic patients, the cognitive decline associated with diabetes is often overlooked. The purpose of this study is to investigate the prevalence of cognitive impairment and its associated risk factors among patients with type 2 diabetes mellitus (T2DM). An observational cross-sectional study was conducted for two months. The Montreal Cognitive Assessment (MoCA) test, which consists of 30 questions, was used to assess cognitive function. In-depth clinical history along with glycaemic parameters were collected. The chi-square test was used to find out the association between categorical variables and cognitive impairment. Pearson's correlation test was performed to determine the correlation between glycaemic parameters and cognitive impairment. A total of 96 patients participated in the study. The mean HbA1c (%) was 9.08 ± 1.73, and the mean MoCA score was 25.14 ± 1.63. Mild cognitive impairment (MCI) was noted in 56% patients. Attention was the most common cognitive domain defect found in all MCI patients-100%. Delayed recall and memory were the second most common cognitive domain defect found-92.5%. Higher HbA1c, high FBS and higher PPBS were found to be statistically associated with MCI. A negative correlation was found between glycaemic parameters (HbA1c, FBS and PPBS levels) and MoCA scores. More than half of our study participants reported mild cognitive impairment. It highlights the need for the implementation of routine cognitive testing for diabetes patients. There is a strong negative correlation between MoCA scores and parameters of glycaemic control; higher levels of HbA1c, FBS, and PPBS are seen in people with a lower MoCA score, indicating mild cognitive impairment. Further studies are needed to evaluate whether improving glucose levels helps in improving cognition or not.

Laparoscopic Roux-en-Y Versus Mini-Gastric Bypass on Liver Function at 6 Months in Morbid Obesity Patients: A Cross-Sectional Study

Background: Various weight loss surgeries exist, with no absolute superiority; each has pros and cons. Due to rising bariatric surgeries globally, it's vital to investigate comparisons between two-mini gastric bypass and Roux-en-Y gastric bypass (RYGB), especially regarding their impact on liver function. Objectives: The purpose of this study was to "draw comparisons between the effects of mini gastric bypass and laparoscopic Roux-en-Y gastric bypass on liver function at 6 months among patients with morbid obesity." Methods: This cross-sectional study included 90 bariatric surgery candidates (Body Mass Index (BMI) 35 - 50) from 2018 - 2021. Forty-five had laparoscopic mini gastric bypass surgery, while 45 had Roux-en-Y gastric bypass. Demographic, anthropometric, lab, and sonographic tests were conducted at baseline, 3-, and 6-months post-surgery. Data was analyzed using SPSS. Results: In a study of 90 patients (75.6% female, mean age 38.6 ± 10.4 years), both surgeries (Mini gastric bypass (MGB) and RYGB) effectively reduced body weight, BMI, and waist circumference at 3- and 6-months post-surgery. However, MGB showed significantly higher BMI and weight loss compared to RYGB (P = 0.003). In 90 patients, both surgeries reduced weight and BMI. However, MGB showed better BMI/weight loss. LFTs (ALT, AST, ALP) remained stable after MGB but worsened at 3 months after RYGB before recovering by 6 months. Mini gastric bypass also showed better GGT improvement. Both procedures improved fatty liver grading, FBS, and HbA1C levels equally. No significant differences were observed in blood pressure, platelet count, hemoglobin, or MCV. Ferritin levels increased in both groups but were higher in RYGB. CRP was higher in RYGB at 3 months. Conclusions: Roux-en-Y gastric bypass temporarily exacerbated liver enzymes and inflammation, but MGB resulted with more weight reduction. In comparison to RYGB, MGB improved LFTs more consistently.

Serum Adiponectin Marker in Women with Polycystic Ovary Syndrome

Background: One of the leading causes of female infertility is polycystic ovarian syndrome (PCOS). Adiponectin is one of many adipokines adipose tissue releases that affect insulin resistance (IR). Objective: To measure PCOS participants' IR, adiponectin, and serum insulin levels. Materials and Procedures: a case-control study involving 80 patients with PCOS (40 obese and 40 nonobese) and 80 controls (40 obesity and 40 nonobese). Adiponectin was measured using an enzyme-linked immunosorbent assay, while serum levels of insulin and FBS were measured using a chemiluminescent automated immunoassay system (ECL). Results: Regardless of body mass index and PCOS, women had lower levels of adiponectin and higher levels of blood fasting glucose, insulin, and IR compared to the relevant with a p-value of ≤0.001 for controls. Conclusion: According to weight, blood adiponectin levels inversely correspond to IR. It can, therefore, act as an indicator in PCOS-affected women.

Preptin as a Potential Marker in Iraqi Newly Diagnosed T2DM and T2DM with cardiovascular disease.

Objective: The aim of present work is to study the Role of preptin level in Iraqi type 2 diabetes patients and related with other biochemical parameters. Methods: This study was including (88) partespents, (22) newly diagnosed T2DM, (22) T2DM and (22) ischemic heart disease with T2DM, and (22) as healthy control, age ranged (35-63) years. Results: The findings indicate that individuals with type 2 diabetes mellitus (T2DM) exhibited markedly elevated levels of FBS, HbA1C, insulin, HOMA-IR, TC, TG, LDL-C, VLDL-C, and preptin in comparison to the control group. These differences were statistically significant (p&lt;0.0001). Moreover, the Pearson correlation analysis revealed that preptin levels were positively associated with FBS, HbA1c, TC, TG, LDL, VLDL, insulin, and HOMA-IR while exhibiting a negative correlation with HDL. Conclusion: Because preptin plays a critical function in controlling sugar metabolism and, consequently, sugar problems, excessive levels of preptin play a significant role in the patient's inability to control both their level of glycosylated hemoglobin and their blood sugar levels. preptin levels are therefore high in diabetics and those with heart disease, which results in a loss of control over the body's metabolism and exposes a patient to many other ailments.

Impact of Probiotics on Gastrointestinal Function and Metabolic Status After Roux-en-Y Gastric Bypass: A Double-Blind, Randomized Trial.

Postoperative changes in gut microbiota may occur in patients undergoing Roux-en-Y gastric bypass surgery. In this study, we evaluate the impact of administering probiotic tablets on the gastrointestinal function and metabolic status of these patients. This double-blinded randomized clinical trial was conducted from 2021 to 2022 on 135 Roux-en-Y surgery candidates. The intervention group underwent the surgical procedure and started receiving probiotic supplements (Familact Co.) 1 week after surgery; the control group received a placebo. The laboratory and anthropometric data were measured and analyzed before and 3 and 6 months after the intervention. GIQLI questionnaire was also used at the beginning and 6 months after the intervention to evaluate GI symptoms. We observed significantly reduced BMI in both groups after surgeries (P < 0.001). The levels of FBS and HbA1C were significantly lower in the probiotic group compared to the placebo in 3 months (P = 0.02 and P = 0.001, respectively) and 6months (P < 0.001 for both) after the intervention. The levels of vitamin B12 increased significantly in the probiotic group (P < 0.001), and the values were substantially higher than the placebo group in 3 and 6 months (P < 0.001), respectively. Analysis of the GIQLI questionnaire before and 6 months after interventions also revealed significant improvement in the GIQLI score in both groups (P < 0.001 for probiotics and P = 0.03 for placebo). Probiotic supplement administration following RYGB improves patients' vitamin and metabolic profile, as well as GI function, although it cannot significantly affect weight loss.